Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LS301-IT in Breast Cancer Surgery
NCT05900986Phase 2Completed
- Sponsor
- Integro Theranostics
- Start
- Jul 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of ls301 in breast cancer, ductal carcinoma in situ (DCIS), sponsored by Integro Theranostics. Started Jul 2023; status: completed.
02
Drugs
ls301
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT05900986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900986.